{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CYP+Cocktail", "query": { "intervention": "CYP Cocktail" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 24, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CYP+Cocktail&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-06T14:05:12.310Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07710768", "title": "A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Obesity", "Overweight" ], "interventions": [ { "name": "UBT251", "type": "DRUG" }, { "name": "Cocktail (Warfarin/Caffeine/Midazolam)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 44, "start_date": "2026-07-15", "completion_date": "2027-04-07", "has_results": false, "last_update_posted_date": "2026-08-18", "last_synced_at": "2026-09-06T14:05:12.310Z", "location_count": 1, "location_summary": "Cypress, California", "locations": [ { "city": "Cypress", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07710768" }, { "nct_id": "NCT05891119", "title": "Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Atopic Dermatitis" ], "interventions": [ { "name": "Caffeine", "type": "DIETARY_SUPPLEMENT" }, { "name": "Metoprolol", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Warfarin", "type": "DRUG" }, { "name": "Vitamin K", "type": "DIETARY_SUPPLEMENT" }, { "name": "Omeprazole", "type": "DRUG" }, { "name": "Rocatinlimab", "type": "DRUG" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 21, "start_date": "2023-06-03", "completion_date": "2025-02-12", "has_results": false, "last_update_posted_date": "2025-12-23", "last_synced_at": "2026-09-06T14:05:12.310Z", "location_count": 7, "location_summary": "North Hollywood, California • DeLand, Florida • Hialeah, Florida + 4 more", "locations": [ { "city": "North Hollywood", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Dilworth", "state": "Minnesota" }, { "city": "Camp Hill", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05891119" }, { "nct_id": "NCT01473888", "title": "A Study To Evaluate The Effect of T89(Dantonic®)On P450 Enzymes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Stable Angina" ], "interventions": [ { "name": "T89(Dantonic)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tasly Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 24, "start_date": "2011-01", "completion_date": "2012-01", "has_results": false, "last_update_posted_date": "2012-11-08", "last_synced_at": "2026-09-06T14:05:12.310Z", "location_count": 1, "location_summary": "Tacoma, Washington", "locations": [ { "city": "Tacoma", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01473888" }, { "nct_id": "NCT03333824", "title": "Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumours" ], "interventions": [ { "name": "CYP1A2 (caffeine)", "type": "DRUG" }, { "name": "CYP2C19 (omeprazole)", "type": "DRUG" }, { "name": "CYP3A (midazolam)", "type": "DRUG" }, { "name": "Kytril (granisetron)", "type": "DRUG" }, { "name": "Wee-1 kinase inhibitor AZD1775", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 33, "start_date": "2017-12-01", "completion_date": "2019-01-22", "has_results": false, "last_update_posted_date": "2019-03-25", "last_synced_at": "2026-09-06T14:05:12.310Z", "location_count": 7, "location_summary": "Bingham Farms, Michigan • Detroit, Michigan • Lebanon, New Hampshire + 4 more", "locations": [ { "city": "Bingham Farms", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Lebanon", "state": "New Hampshire" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT03333824" }, { "nct_id": "NCT05967689", "title": "A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations" ], "interventions": [ { "name": "TAS6417", "type": "DRUG" }, { "name": "CYP Cocktail", "type": "DRUG" }, { "name": "Transporter Cocktail", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Taiho Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 220, "start_date": "2023-07-31", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-09-01", "last_synced_at": "2026-09-06T14:05:12.310Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Duarte, California • Boston, Massachusetts + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Basking Ridge", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05967689" }, { "nct_id": "NCT06092931", "title": "A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "DC-806", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Repaglinide", "type": "DRUG" }, { "name": "Digoxin", "type": "DRUG" }, { "name": "Rosuvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 28, "start_date": "2023-10-16", "completion_date": "2023-11-28", "has_results": false, "last_update_posted_date": "2024-01-11", "last_synced_at": "2026-09-06T14:05:12.310Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT06092931" }, { "nct_id": "NCT02993471", "title": "A Study of Ixekizumab in Participants With Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "Drug Cocktail", "type": "DRUG" }, { "name": "Ixekizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2016-12-22", "completion_date": "2017-11-21", "has_results": true, "last_update_posted_date": "2019-03-12", "last_synced_at": "2026-09-06T14:05:12.310Z", "location_count": 3, "location_summary": "Anaheim, California • DeLand, Florida • High Point, North Carolina", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "High Point", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02993471" }, { "nct_id": "NCT02578277", "title": "Study on Effects of BMS-955176 on the Pharmacokinetics of Probe Substrates", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "CYP and transporter probe substrates", "type": "DRUG" }, { "name": "BMS-955176", "type": "DRUG" }, { "name": "BMS-955176 plus CYP and transporter probe substrates", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 59, "start_date": "2015-11-09", "completion_date": "2015-12-23", "has_results": false, "last_update_posted_date": "2018-07-13", "last_synced_at": "2026-09-06T14:05:12.310Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02578277" }, { "nct_id": "NCT05657613", "title": "Drug-Drug Interaction Study of Pacritinib and CYP450,Transporter Substrates, and CYP450 3A4 in Healthy Male Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug Interactions" ], "interventions": [ { "name": "CYP450 Cocktail and Transporter Substrates with Pacritinib", "type": "DRUG" }, { "name": "Part 2 -Group A Bosentan 125 mg (CYP450 3A4 inducer) with Pacritinib", "type": "DRUG" }, { "name": "Part 2 Group B - Fluconazole (CYP450 3A4 inhibitor) with Pacritinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CTI BioPharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "MALE", "summary": "18 Years to 55 Years · Male only" }, "enrollment_count": 60, "start_date": "2023-01-03", "completion_date": "2023-06-08", "has_results": false, "last_update_posted_date": "2024-10-17", "last_synced_at": "2026-09-06T14:05:12.310Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05657613" }, { "nct_id": "NCT04201197", "title": "Interactions Between Cannabinoids and Cytochrome P450-Metabolized Drugs", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug-Interactions" ], "interventions": [ { "name": "Inje cocktail", "type": "DRUG" }, { "name": "THC Cannabis extract", "type": "DRUG" }, { "name": "THC/CBD Cannabis Extract", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 22, "start_date": "2020-11-10", "completion_date": "2022-07-28", "has_results": true, "last_update_posted_date": "2023-07-24", "last_synced_at": "2026-09-06T14:05:12.310Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04201197" } ] }